All In Biotech

Drug Trial Radar · NCT07244003

Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control

Efficacy and Safety of the Triple Combination Therapy of Met/SGLT-2i/GLP-1RA or Other Oral Antidiabetic Drugs in Patients With Type 2 Diabetes Exhibiting Poor Glycemic Control

Last checked: Nov 20, 2026Latest source record: Nov 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 430 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

430

Planned (sponsor's estimate)

Start

Mar 29, 2025

Primary completion

Dec 31, 2027

Study completion Jun 30, 2028

Sponsor

Sponsor type
Industry
First posted
Nov 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective of this study is to compare the efficacy and safety of the triple combination therapy of Met/SGLT-2i/GLP-1RA or other oral antidiabetic drugs in patients with type 2 diabetes exhibiting poor glycemic control.

Conditions

  • T2DM (Type 2 Diabetes Mellitus)

Interventions

  • MetforminDrug

    The dosage of metformin hydrochloride was consistent with baseline.

  • Triple Therapy of Other Oral Antidiabetic DrugsDrug

    The dosage of metformin hydrochloride was consistent with baseline. The usage and dosage of other hypoglycemic drugs were referred to their respective instructions.

  • ganagliflozinDrug

    Ganagliflozin tablet : 50mg/d.

  • liraglutideDrug

    Liraglutide injection: 0.6 mg/d for the first week, 1.2 mg/d for the second week, and 1.8 mg/d after the third week.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The change of HbA1c compared to the baselineTime frame: from baseline to week 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tianjin Medical University General Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.